Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pliant Therapeutics (PLRX) Shares Issued (2019 - 2023)

Pliant Therapeutics (PLRX) has disclosed Shares Issued for 5 consecutive years, with $270.3 million as the latest value for Q1 2023.

  • On a quarterly basis, Shares Issued changed N/A to $270.3 million in Q1 2023 year-over-year; TTM through Dec 2023 was $270.3 million, a 25.0% increase, with the full-year FY2023 number at $270.3 million, up 25.0% from a year prior.
  • Shares Issued was $270.3 million for Q1 2023 at Pliant Therapeutics, up from $216.2 million in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $270.3 million in Q1 2023 to a low of -$1.7 million in Q3 2021.
  • A 5-year average of $55.2 million and a median of $371000.0 in 2021 define the central range for Shares Issued.
  • Peak YoY movement for Shares Issued: crashed 96.28% in 2021, then soared 12518.21% in 2022.
  • Pliant Therapeutics' Shares Issued stood at $28000.0 in 2019, then surged by 35521.43% to $10.0 million in 2020, then crashed by 117.46% to -$1.7 million in 2021, then skyrocketed by 12518.21% to $216.2 million in 2022, then increased by 25.0% to $270.3 million in 2023.
  • Per Business Quant, the three most recent readings for PLRX's Shares Issued are $270.3 million (Q1 2023), $216.2 million (Q3 2022), and -$1.7 million (Q3 2021).